Code | 8388A | ||||||||||
MA number | EU/1/13/882/001 | ||||||||||
Product Form: | plu igf 1x300 mg+1x2 ml+samost.bal.(liek.inj.skl.) | ||||||||||
MA Status: | E - Valid centralised marketing authorisation | ||||||||||
Type of procedure: | EU | ||||||||||
MAH, country: | Otsuka Pharmaceutical Netherlands B.V., Netherland | ||||||||||
Therapeutic Class: | 68 - ANTIPSYCHOTICA (NEUROLEPTICA) | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 36 | ||||||||||
Route of admin.: | Intramuscular use |
Prescription Status: | Medicinal product subject to medical prescription. |
Legal basis: | Article 8(3) application - known active substance |
MA issued: | 15.11.2013 |
SmPC + PL: | European Medicines Agency's database |
Safety feature | Yes |
Data update: | 24.04.2024 |